https://orcid.org/0000-0002-3782-6645
References
- Ahrén B. 2003. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 3(5):365–372.
- Boulton DW. 2017. Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clin Pharmacokinet. 56(1):11–24.
- Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. 1995. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44(9):1126–1131.
- Drucker DJ. 2003. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 12(1):87–100.
- Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR. 1999. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 48(1):86–93.
- Fuchs H, Tillement J-P, Urien S, Greischel A, Roth W. 2009. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol. 61(1):55–62.
- Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Michael T, Tanaka W, Wang AQ, et al. 2005. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo controlled studies with single oral doses. Clin Pharmacol Ther. 78(6):675–688.
- Golightly LK, Drayna CC, McDermott MT. 2012. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 51(8):501–514.
- Holst JJ, Deacon CF. 1998. Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes. Diabetes. 47(11):1663–1670.
- Hop CE, Wang Z, Chen Q, Kwei G. 1998. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci. 87(7):901–903.
- Kreymann B, Williams G, Ghatei MA, Bloom SR. 1987. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 2(8571):1300–1304.
- Krieter PA, Colletti AE, Doss GA, Miller RR. 1994. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab Dispos. 22(4):625–630.
- Lu J, Bian Y, Zhang H, Tang D, Tian X, Zhou X, Xu Z, Ding J, Yu Q, Xiong Y, et al. 2022. The Metabolism and Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C] Cetagliptin in Healthy Volunteers. Xenobiotica. 52(1):38–45.
- Lu J, Tian X, Tang D, Zhou X, Xu Z, Ding J, Wang T, Yu Q, Ding J. 2021. In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers. Xenobiotica. 51(10):1122–1131.
- Lu J, Wang L, Zhou S, Zhou C, Xie L, Chen J, Tang D, Tian X, Xie D, Ding J, et al. 2022. A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin. Br J Clin Pharmacol. 88(6):2946–2958.
- Sunkara G, Sabo R, Wang Y, He Y-L, Campestrini J, Rosenberg M, Howard D, Dole WP. 2007. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 47(9):1152–1158.
- The State Council, The People’s Republic of China. 2017. Good Laboratory Practice. Available from: http://www.gov.cn/gongbao/content/2017/content_5241929.htm.
- Wang L, Lu J, Zhou S, Zhao Y, Xie L, Zhou C, Chen J, Ding S, Xie D, Ding J, et al. 2021. First-in-Human, single‑ascending dose and food effect studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of cetagliptin, a dipeptidyl peptidase‑4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Drug Investig. 41(11):999–1010.
- Wang L, Lu J, Zhou S, Zhao Y, Xie L, Zhou C, Chen J, Ding S, National Research Council of the National Academy of Sciences 2011. Guide for the Care and Use of Laboratory Animals. Available from: https://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-use-of-laboratory-animals.pdf.